Prognostic assessment of apoptotic gene polymorphisms in non-small cell lung cancer in Chinese
暂无分享,去创建一个
Hongbing Shen | Zhibin Hu | G. Jin | J. Dai | Hongxia Ma | S. Cao | Cheng Wang | Lingmin Hu | Yao Liu | Lin Xu | Jiaping Chen | Xin'en Huang | Songyu Cao | Hongxia Ma
[1] Q. Wei,et al. TNFRSF1B +676 T>G polymorphism predicts survival of non-Small cell lung cancer patients treated with chemoradiotherapy , 2011, BMC Cancer.
[2] C. Kimchi-Sarfaty,et al. Understanding the contribution of synonymous mutations to human disease , 2011, Nature Reviews Genetics.
[3] C. Mathers,et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.
[4] H. Jeon,et al. Polymorphisms in Apoptosis-Related Genes and Survival of Patients with Early-Stage Non-Small-Cell Lung Cancer , 2010, Annals of Surgical Oncology.
[5] Hongbing Shen,et al. A 3′-Untranslated Region Polymorphism in IGF1 Predicts Survival of Non–Small Cell Lung Cancer in a Chinese Population , 2010, Clinical Cancer Research.
[6] Kihyun Kim,et al. BCL2 gene polymorphism could predict the treatment outcomes in acute myeloid leukemia patients. , 2010, Leukemia research.
[7] Dong Sun Kim,et al. Polymorphisms in the CASPASE genes and survival in patients with early-stage non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] T. Cotter,et al. Apoptosis and cancer: the genesis of a research field , 2009, Nature Reviews Cancer.
[9] A. Bankfalvi,et al. The regulatory BCL2 promoter polymorphism (-938C>A) is associated with relapse and survival of patients with oropharyngeal squamous cell carcinoma. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] S. Kam,et al. Polymorphisms in the FAS and FASL Genes and Survival of Early Stage Non–small Cell Lung Cancer , 2009, Clinical Cancer Research.
[11] Boguslaw Stec,et al. The Fas/FADD death domain complex structure unravels signaling by receptor clustering , 2008, Nature.
[12] Ping Yang,et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. , 2008, Mayo Clinic proceedings.
[13] R. Ankathil,et al. p53 Arg72Pro Polymorphism Predicts Survival Outcome in Lung Cancer Patients in Indian Population , 2008, Cancer investigation.
[14] R. Kimmig,et al. The AA Genotype of the Regulatory BCL2 Promoter Polymorphism (−938C>A) Is Associated with a Favorable Outcome in Lymph Node–Negative Invasive Breast Cancer Patients , 2007, Clinical Cancer Research.
[15] K. Jöckel,et al. Association of a novel regulatory polymorphism (-938C>A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia. , 2007, Blood.
[16] J. Park,et al. Caspase 9 promoter polymorphisms and risk of primary lung cancer. , 2006, Human molecular genetics.
[17] K. Vermeulen,et al. Apoptosis: mechanisms and relevance in cancer , 2005, Annals of Hematology.
[18] Sunil Singhal,et al. Prognostic Implications of Cell Cycle, Apoptosis, and Angiogenesis Biomarkers in Non–Small Cell Lung Cancer: A Review , 2005, Clinical Cancer Research.
[19] Nathaniel Rothman,et al. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. , 2004, Journal of the National Cancer Institute.
[20] L. Owen-Schaub,et al. Adenoviral Bid Overexpression Induces Caspase-dependent Cleavage of Truncated Bid and p53-independent Apoptosis in Human Non-small Cell Lung Cancers* , 2003, Journal of Biological Chemistry.
[21] M. Brundage,et al. Prognostic factors in non-small cell lung cancer: a decade of progress. , 2002, Chest.
[22] T. Lumley,et al. Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker , 2000, Biometrics.
[23] M. Volm,et al. Relevance of proliferative and pro-apoptotic factors in non-small-cell lung cancer for patient survival , 2000, British Journal of Cancer.
[24] M. Volm,et al. Expression of FAS (CD95/APO‐1) and FAS ligand in lung cancer, its prognostic and predictive relevance , 1999, International journal of cancer.
[25] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[26] Junying Yuan,et al. Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the Fas Pathway of Apoptosis , 1998, Cell.
[27] C. Kitanaka,et al. Apoptosis in cancer. , 1996, Human cell.
[28] L. Leslie,et al. A decade of progress. , 1969, Minnesota medicine.